Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Eli Lilly has set the health and finance worlds abuzz with its new weight-loss pill, orforglipron. The company reported impressive trial outcomes, showing the drug outperformed Ozempic—a leading ...

On an adjusted basis, Lilly earned $3.34 per share for the quarter, compared with analysts’ estimates of $3.02 per share ...

Shares of Eli Lilly (LLY ... participants taking orforglipron lost an average of 16.0 lbs at the highest dose. Given that participants had not yet reached a weight plateau at the time the study ...

The highly anticipated results of the trial conducted by pharmaceutical company Eli Lilly found that the pill helped people lose weight and lower blood sugar levels, positioning it alongside new ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...

Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to ...

Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its weight-loss pill Orforglipron, which is thought to be a needle-free alternative ...

The highest dose of the pill helped patients lose 7.9% of their weight, or around 16 pounds, on average after 40 weeks. Eli Lilly also said patients saw no plateau in their weight loss by the time ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, sending shares in the US drugmaker up nearly 15 per cent in Wall Street ...